RT Journal Article
SR Electronic
T1 A clinical trial to evaluate the dayzz smartphone app on employee sleep, health, and productivity at a large US employer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264618
DO 10.1101/2021.10.06.21264618
A1 Rebecca Robbins
A1 Matthew D. Weaver
A1 Stuart F. Quan
A1 Jason P. Sullivan
A1 Mairav Cohen-Zion
A1 Laura Glasner
A1 Salim Qadri
A1 Charles A. Czeisler
A1 Laura Barger
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264618.abstract
AB Sleep deficiency is a hidden cost of our 24-7 society, with 70% of adults in the US admitting that they routinely obtain insufficient sleep. Further, it is estimated that 50-70 million adults in the US have a sleep disorder. Undiagnosed and untreated sleep disorders are associated with diminished health for the individual and increased costs for the employer. Research has shown that adverse impacts on employees and employers can be mitigated through sleep health education and sleep disorder screening and treatment programs. Smartphone applications (app) are increasingly commonplace and represent promising, scalable modalities for such programs. The dayzz app is a personalized sleep training program that incorporates assessment of sleep disorders and offers a personalized comprehensive sleep improvement solution. Using a sample of day workers affiliated with a large institution of higher education, we will conduct a single-site, parallel-group, randomized, waitlist control trial. Participants will be randomly assigned to either use the dayzz app throughout the study or receive the dayzz app at the end of the study. We will collect data on feasibility and acceptability of the dayzz app; employee sleep, including sleep behavioral changes, sleep duration, regularity, and quality; employee presenteeism, absenteeism, and performance; employee mood; adverse and safety outcomes; and healthcare utilization on a monthly basis throughout the study, as well as collect more granular daily data from the employee during pre-specified intervals. Our results will illuminate whether a personalized smartphone app is a viable approach for improving employee sleep, health, and productivity.Competing Interest StatementDr. Cohen-Zion and Ms. Glasner are employees at dayzz Live ell, Ltd. Dr. Weaver reports consulting fees from the National Sleep Foundation and the University of Pittsburgh. Dr. Barger reports consulting fees from Puget Sound Pilots and Boston Childrens Hospital. Dr. Robbins reports personal fees from SleepCycle, Rituals Cosmetics, Denihan Hospitality, and With Deep. Dr. Weaver reports personal fees from the University of Pittsburgh and the National Sleep Foundation. Dr. Quan has served as a consultant for Best Doctors, Jazz Pharmaceuticals and Whispersom. Dr. Barger reports personal fees from the University of Pittsburgh, CurAegis, Casis, Puget Sound Pilots, and Boston Childrens Hospital. Dr. Czeisler is/was a paid consultant to or speaker for Ganesco, Inc., Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physician's Seal, Samsung, State of Washington Board of Pilotage Commissioners, Tencent Holdings Ltd, Teva Pharma Australia, and Vanda Pharmaceuticals Inc, in which Dr. Czeisler holds an equity interest; received travel support from Aspen Brain Institute, Bloomage International Investment Group, Inc., UK Biotechnology and Biological Sciences Research Council, Bouley Botanicals, Dr. Stanley Ho Medical Development Foundation, Illuminating Engineering Society, National Safety Council, Tencent Holdings Ltd, and The Wonderful Company; receives research/education support through BWH from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences LLC, Jazz Pharmaceuticals PLC Inc, Johnson & Johnson, NeuroCare, Inc., Philips Respironics Inc/Philips Homecare Solutions, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries Ltd, Sanofi SA, Optum, ResMed, San Francisco Bar Pilots, Sanofi, Schneider, Simmons, Sysco, Philips, Vanda Pharmaceuticals; is/was an expert witness in legal cases, including those involving Advanced Power Technologies, Aegis Chemical Solutions LLC, Amtrak; Casper Sleep Inc, C&J Energy Services, Complete General Construction Co, Dallas Police Association, Enterprise Rent-A-Car, Steel Warehouse, FedEx, Greyhound Lines, Palomar Health District, PAR Electrical Contractors, Product & Logistics Services LLC, Puckett Emergency Medical Services LLC, South Carolina Central Railroad Company LLC, Union Pacific Railroad, UPS, and Vanda Pharmaceuticals; serves as the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc.; and receives royalties from McGraw Hill, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. COI for Dr. Czeisler have been reviewed and are managed by the Brigham and Womens Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Copyright 2000-2020 Charles A. Czeisler and Brigham and Womens Hospital.Clinical TrialNCT04224285Funding StatementThis trial is supported by a grant from dayzz Live Well, Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The funders did have a role in preparation of the manuscript. Specifically, MCZ and LG, who are employees of dayzz reviewed the manuscript and contributed to the manuscript portion describing the dayzz app. dayzz holds patents pertaining to its software. This research did not result in any additional patents.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Partners HealthCare Institutional Review Board (IRB) on February 10, 2020 (Protocol #: 2019P003277).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo datasets have been generated or analyzed. This submission is a protocol paper. The data availability policy is not applicable to this article.